Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Equity Average (2019 - 2025)

Historic Equity Average for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $77.5 million.

  • aTYR PHARMA's Equity Average rose 581.12% to $77.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 581.12%. This contributed to the annual value of $80.3 million for FY2024, which is 78.11% down from last year.
  • As of Q3 2025, aTYR PHARMA's Equity Average stood at $77.5 million, which was up 581.12% from $74.9 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Equity Average high stood at $113.3 million for Q4 2021, and its period low was $40.6 million during Q1 2021.
  • Its 5-year average for Equity Average is $82.2 million, with a median of $81.7 million in 2022.
  • In the last 5 years, aTYR PHARMA's Equity Average surged by 25598.24% in 2021 and then crashed by 3454.86% in 2022.
  • Quarter analysis of 5 years shows aTYR PHARMA's Equity Average stood at $113.3 million in 2021, then plummeted by 34.55% to $74.1 million in 2022, then rose by 27.36% to $94.4 million in 2023, then dropped by 28.44% to $67.6 million in 2024, then rose by 14.74% to $77.5 million in 2025.
  • Its last three reported values are $77.5 million in Q3 2025, $74.9 million for Q2 2025, and $72.5 million during Q1 2025.